BlackRock’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $478M | Buy |
3,047,988
+98,228
| +3% | +$14.7M | 0.01% | 1246 |
|
|
2026
Q1 | $451M | Buy |
2,949,760
+141,669
| +5% | +$21.7M | 0.01% | 1194 |
|
|
2025
Q4 | $387M | Buy |
2,808,091
+277,885
| +11% | +$36.4M | 0.01% | 1276 |
|
|
2025
Q3 | $324M | Buy |
2,530,206
+209,051
| +9% | +$25.5M | 0.01% | 1353 |
|
|
2025
Q2 | $281M | Buy |
2,321,155
+153,265
| +7% | +$17.3M | 0.01% | 1408 |
|
|
2025
Q1 | $242M | Buy |
2,167,890
+203,934
| +10% | +$21.7M | 0.01% | 1487 |
|
|
2024
Q4 | $191M | Buy |
1,963,956
+16,051
| +0.8% | +$1.71M | ﹤0.01% | 1697 |
|
|
2024
Q3 | $224M | Buy |
1,947,905
+80,752
| +4% | +$9.16M | ﹤0.01% | 1589 |
|
|
2024
Q2 | $199M | Buy |
1,867,153
+8,353
| +0.4% | +$838K | ﹤0.01% | 1625 |
|
|
2024
Q1 | $180M | Buy |
1,858,800
+29,277
| +2% | +$3M | ﹤0.01% | 1712 |
|
|
2023
Q4 | $185M | Buy |
1,829,523
+105,587
| +6% | +$10.2M | ﹤0.01% | 1696 |
|
|
2023
Q3 | $176M | Sell |
1,723,936
-1,071
| -0.1% | -$109K | 0.01% | 1622 |
|
|
2023
Q2 | $174M | Buy |
1,725,007
+106,966
| +7% | +$10.7M | ﹤0.01% | 1687 |
|
|
2023
Q1 | $149M | Buy |
1,618,041
+85,903
| +6% | +$7.5M | ﹤0.01% | 1764 |
|
|
2022
Q4 | $139M | Buy |
1,532,138
+140,569
| +10% | +$11.8M | ﹤0.01% | 1785 |
|
|
2022
Q3 | $106M | Sell |
1,391,569
-153,713
| -10% | -$12.7M | ﹤0.01% | 1914 |
|
|
2022
Q2 | $131M | Sell |
1,545,282
-11,257
| -0.7% | -$988K | ﹤0.01% | 1853 |
|
|
2022
Q1 | $137M | Buy |
1,556,539
+240,710
| +18% | +$20.8M | ﹤0.01% | 1929 |
|
|
2021
Q4 | $115M | Sell |
1,315,829
-75,861
| -5% | -$6.3M | ﹤0.01% | 2122 |
|
|
2021
Q3 | $114M | Sell |
1,391,690
-48,877
| -3% | -$4.4M | ﹤0.01% | 2129 |
|
|
2021
Q2 | $131M | Buy |
1,440,567
+190,337
| +15% | +$16.9M | ﹤0.01% | 2085 |
|
|
2021
Q1 | $107M | Buy |
1,250,230
+557,281
| +80% | +$50M | ﹤0.01% | 2159 |
|
|
2020
Q4 | $65.4M | Sell |
692,949
-284,823
| -29% | -$24.9M | ﹤0.01% | 2314 |
|
|
2020
Q3 | $85M | Buy |
977,772
+34,255
| +4% | +$2.97M | ﹤0.01% | 1978 |
|
|
2020
Q2 | $82.4M | Sell |
943,517
-95,198
| -9% | -$8.22M | ﹤0.01% | 1967 |
|
|
2020
Q1 | $85.6M | Sell |
1,038,715
-3,414,096
| -77% | -$305M | ﹤0.01% | 1746 |
|
|
2019
Q4 | $422M | Buy |
4,452,811
+2,325,948
| +109% | +$209M | 0.02% | 932 |
|
|
2019
Q3 | $185M | Sell |
2,126,863
-2,874,098
| -57% | -$258M | 0.01% | 1461 |
|
|
2019
Q2 | $457M | Sell |
5,000,961
-6,327,532
| -56% | -$536M | 0.02% | 806 |
|
|
2019
Q1 | $976M | Sell |
11,328,493
-1,437,764
| -11% | -$115M | 0.04% | 423 |
|
|
2018
Q4 | $982M | Buy |
12,766,257
+8,819,708
| +223% | +$687M | 0.05% | 368 |
|
|
2018
Q3 | $305M | Sell |
3,946,549
-327,251
| -8% | -$24.2M | 0.01% | 1161 |
|
|
2018
Q2 | $289M | Sell |
4,273,800
-14,641
| -0.3% | -$1.01M | 0.01% | 1143 |
|
|
2018
Q1 | $311M | Sell |
4,288,441
-192,926
| -4% | -$14.7M | 0.01% | 1042 |
|
|
2017
Q4 | $337M | Buy |
4,481,367
+340,626
| +8% | +$25.7M | 0.02% | 985 |
|
|
2017
Q3 | $319M | Buy |
4,140,741
+179,183
| +5% | +$13.5M | 0.02% | 978 |
|
|
2017
Q2 | $296M | Buy |
3,961,558
+800,380
| +25% | +$56.7M | 0.02% | 999 |
|
|
2017
Q1 | $210M | Buy |
+3,161,178
| New | +$211M | 0.01% | 1248 |
|
|
2016
Q4 | – | Sell |
-558
| Closed | -$39K | – | 3790 |
|
|
2016
Q3 | $39K | Sell |
558
-389
| -41% | -$28.3K | ﹤0.01% | 3082 |
|
|
2016
Q2 | $70K | Buy |
+947
| New | +$65.4K | ﹤0.01% | 2765 |
|
|
2014
Q3 | – | Sell |
-907
| Closed | -$74K | – | 3186 |
|
|
2014
Q2 | $74K | Buy |
+907
| New | +$71.3K | ﹤0.01% | 1796 |
|
Other funds holding NVS
BlackRock's NVS Position: Q2 2026 in Review
BlackRock increased its Novartis (NVS) stake by 3.3% in Q2 2026, buying an estimated $14.7M and bringing the position to 3,047,988 shares worth $478M. The position accounts for 0.01% of the portfolio, ranked #1246.
BlackRock first reported a position in NVS in Q2 2014 and has held it in 41 quarters since. The position peaked at $982M in Q4 2018. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- BlackRock held 3,047,988 shares of Novartis worth $478M as of Q2 2026.
- BlackRock bought 98,228 Novartis shares in Q2 2026, an estimated $14.7M.
- Novartis made up 0.01% of BlackRock's portfolio in Q2 2026, its #1246 holding.
- BlackRock first reported a position in Novartis in Q2 2014 and has held it in 41 quarters since.
- BlackRock's Novartis position peaked at $982M in Q4 2018.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.